Judith Brownell

715 total citations
31 papers, 540 citations indexed

About

Judith Brownell is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cellular and Molecular Neuroscience. According to data from OpenAlex, Judith Brownell has authored 31 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Surgery and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Judith Brownell's work include Pituitary Gland Disorders and Treatments (15 papers), Growth Hormone and Insulin-like Growth Factors (10 papers) and Adrenal and Paraganglionic Tumors (9 papers). Judith Brownell is often cited by papers focused on Pituitary Gland Disorders and Treatments (15 papers), Growth Hormone and Insulin-like Growth Factors (10 papers) and Adrenal and Paraganglionic Tumors (9 papers). Judith Brownell collaborates with scholars based in Netherlands, Switzerland and United Kingdom. Judith Brownell's co-authors include Emilio del Pozo, Leif Wide, Torbjörn Bergh, A. J. van der Lely, Rolf C. Gaillard, Steven W. J. Lamberts, Howard S. Jacobs, R. Rolland, Roy Homburg and E. del Pozo and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Clinical Endocrinology & Metabolism and Brain Research.

In The Last Decade

Judith Brownell

31 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Judith Brownell Netherlands 15 382 218 85 74 66 31 540
Masami Ono Japan 12 526 1.4× 185 0.8× 64 0.8× 34 0.5× 110 1.7× 24 684
Eva Grenbäck Sweden 9 367 1.0× 131 0.6× 41 0.5× 26 0.4× 45 0.7× 13 539
S. R. Crosby United Kingdom 11 194 0.5× 57 0.3× 23 0.3× 62 0.8× 58 0.9× 12 394
Shinji Sawano Japan 11 377 1.0× 109 0.5× 56 0.7× 8 0.1× 88 1.3× 38 571
S. Bornstein Germany 15 305 0.8× 82 0.4× 101 1.2× 16 0.2× 169 2.6× 18 685
R. Lamberts Germany 15 86 0.2× 407 1.9× 89 1.0× 26 0.4× 110 1.7× 30 792
N Yanaihara Japan 11 103 0.3× 133 0.6× 180 2.1× 17 0.2× 133 2.0× 34 462
Debra A. Schell United States 6 71 0.2× 75 0.3× 190 2.2× 12 0.2× 162 2.5× 8 326
Donald R. Hodges United States 8 145 0.4× 105 0.5× 33 0.4× 7 0.1× 101 1.5× 13 356
G Forsbach Mexico 10 95 0.2× 65 0.3× 85 1.0× 6 0.1× 62 0.9× 32 309

Countries citing papers authored by Judith Brownell

Since Specialization
Citations

This map shows the geographic impact of Judith Brownell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Brownell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Brownell more than expected).

Fields of papers citing papers by Judith Brownell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Brownell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Brownell. The network helps show where Judith Brownell may publish in the future.

Co-authorship network of co-authors of Judith Brownell

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Brownell. A scholar is included among the top collaborators of Judith Brownell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Brownell. Judith Brownell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Halse, Johan, S. J. Bakke, Trine Bjøro, et al.. (1993). Long-term treatment of macroprolactinomas with CV 205-502. European Journal of Endocrinology. 128(4). 301–307. 12 indexed citations
2.
Lappöhn, Richard E., H.B.M. van de Wiel, & Judith Brownell. (1992). The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. Fertility and Sterility. 58(2). 321–327. 7 indexed citations
3.
Brue, Thierry, Isabelle Pellegrini, Ginette Gunz, et al.. (1992). Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.. The Journal of Clinical Endocrinology & Metabolism. 74(3). 577–584. 56 indexed citations
4.
Rasmussen, Carsten, Judith Brownell, & Torbjörn Bergh. (1991). Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. European Journal of Endocrinology. 125(2). 170–176. 17 indexed citations
5.
Lely, A. J. van der, Judith Brownell, & Steven W. J. Lamberts. (1991). The Efficacy and Tolerability of CV 205–502 (a Nonergot Dopaminergic Drug) in Macroprolactinoma Patients and in Prolactinoma Patients Intolerant to Bromocriptine. The Journal of Clinical Endocrinology & Metabolism. 72(5). 1136–1141. 35 indexed citations
6.
Uské, A, Marianne J. Reymond, François Rey, et al.. (1991). CV 205–502 treatment of macroprolactinomas. Journal of Endocrinological Investigation. 14(9). 757–762. 11 indexed citations
7.
Wit, W. de, et al.. (1991). CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. European Journal of Obstetrics & Gynecology and Reproductive Biology. 40(2). 111–118. 23 indexed citations
8.
Kremer, Jan A.M., et al.. (1990). Postpartum return of pituitary and ovarian activity during lactation inhibition with the new dopamine agonist CV 205-502 and during normal lactation. European Journal of Endocrinology. 122(6). 759–765. 5 indexed citations
9.
Homburg, Roy, Christine R. West, Judith Brownell, & Howard S. Jacobs. (1990). A DOUBLE‐BLIND STUDY COMPARING A NEW NON‐ERGOT, LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, WITH BROMOCRIPTINE IN WOMEN WITH HYPERPROLACTINAEMIA. Clinical Endocrinology. 32(5). 565–572. 42 indexed citations
10.
Gaillard, Rolf C., et al.. (1989). Specific Effect of CV 205-502, a Potent Nonergot Dopamine Agonist, During a Combined Anterior Pituitary Function Test*. The Journal of Clinical Endocrinology & Metabolism. 68(2). 329–335. 11 indexed citations
11.
Lappöhn, Richard E., et al.. (1989). The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study. Fertility and Sterility. 52(4). 574–579. 14 indexed citations
12.
Gaillard, Rolf C. & Judith Brownell. (1988). Hormonal effects of CQP 201—403, a new dopamine agonist. European Journal of Endocrinology. 119(3). 452–458. 1 indexed citations
13.
Rolland, R., et al.. (1988). Endocrine effects of CV 205-502, a new dopamine agonist, in hyperprolactinemic women. Gynecological Endocrinology. 2(3). 233–248. 9 indexed citations
14.
Bergh, Torbjörn, et al.. (1988). LONG‐TERM TREATMENT WITH A NEW NON‐ERGOT LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, IN WOMEN WITH HYPERPROLACTINAEMIA. Clinical Endocrinology. 29(3). 271–279. 28 indexed citations
15.
Hanssen, L. E., Judith Brownell, Johan Halse, et al.. (1988). CQP 201-403, a new dopamine agonist in the treatment of hyperprolactinemia. European Journal of Endocrinology. 117(4). 552–556. 4 indexed citations
16.
Gaillard, Rolf C. & Judith Brownell. (1988). Hormonal effects of CV 205–502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties. Life Sciences. 43(17). 1355–1362. 17 indexed citations
17.
Rolland, R., et al.. (1987). Prolactin suppressant effect of CQP 201–403, a new dopamine agonist, in hyperprolactinemic women. Gynecological Endocrinology. 1(1). 93–103. 2 indexed citations
18.
Rasmussen, C, T. Bergh, Leif Wide, & Judith Brownell. (1987). CV 205‐502: A NEW LONG‐ACTING DRUG FOR INHIBITION OF PROLACTIN HYPERSECRETION. Clinical Endocrinology. 26(3). 321–326. 30 indexed citations
19.
Venetikou, Maria S., et al.. (1987). Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumours in vitro. European Journal of Endocrinology. 116(2). 287–292. 13 indexed citations
20.
Pozo, Emilio del & Judith Brownell. (1979). Prolactin. Hormone Research. 10(2-3). 143–174. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masami Ono Breakdown of academic impact, for papers by Eva Grenbäck Breakdown of academic impact, for papers by S. R. Crosby Breakdown of academic impact, for papers by Shinji Sawano Breakdown of academic impact, for papers by S. Bornstein Breakdown of academic impact, for papers by R. Lamberts Breakdown of academic impact, for papers by N Yanaihara Breakdown of academic impact, for papers by Debra A. Schell Breakdown of academic impact, for papers by Donald R. Hodges Breakdown of academic impact, for papers by G Forsbach
Rankless by CCL
2026